
LOPHOS HOLDINGS INC.
CONDENSED INTERIM CONSOLIDATED FINANCIAL
STATEMENTS
THREE MONTHS ENDED JUNE 30, 2023
(EXPRESSED IN CANADIAN DOLLARS)
(UNAUDITED)

Notice to Reader

The accompanying unaudited condensed interim consolidated financial statements of Lophos Holdings Inc. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements as at and for the three months ended June 30, 2023 have not been reviewed by the Company's auditors.

Lophos Holdings Inc.

Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) (Unaudited)

	As at June 30 2023	As at March 31, 2023
ASSETS		
Current assets		
Cash	\$ 270,149	\$ 140,029
Accounts receivable (note 3)	166,734	162,265
Inventory	9,714	9,714
Prepaid expense and advance (note 4)	8,372	219,208
Total current assets	454,969	531,216
Non-current assets		
Fixed assets (note 5)	3,706,812	3,448,539
Total assets	\$ 4,161,781	\$ 3,979,755
LIABILITIES AND EQUITY		
Current liabilities		
Accounts payable and accrued liabilities (note 15(a))	\$ 546,409	\$ 445,281
Due to related parties (note 15(a)(iii))	21,440	21,440
Loan payable (note 8)	55,000	-
	622,849	466,721
Non-current liabilities		
Convertible debenture (notes 6 and 15)	131,633	126,795
Promissory notes (note 7)	1,948,084	1,909,981
Total liabilities	2,702,566	2,503,497
Shareholders' Equity		
Share capital (note 9)	2,115,559	1,981,447
Warrants and special warrants (notes and 10)	364,993	296,605
Contributed surplus (note)	675,160	500,701
Equity portion of convertible debenture	15,625	15,625
Deficit	(1,712,122)	(1,318,120)
Total equity	1,459,215	1,476,258
Total liabilities and shareholders' equity	\$ 4,161,781	\$ 3,979,755

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Business of the Company and going concern (note 1) Subsequent events (note 16)

On Behalf of the Board:

"Solomon Elimminian"
Director

"Jeremy Petsun"
Director

Lophos Holdings Inc.**Condensed Interim Consolidated Statements of loss and Comprehensive loss
(Expressed in Canadian Dollars)
(Unaudited)**

Three months ended June 30,	2023	2022
Expenses		
Salaries and benefits (note 15(b))	\$ 3,358	\$ 36,204
Professional fees (note 15)	144,658	138,383
Depreciation (note 5)	7,015	11,176
Investor relations	-	7,811
Shareholder information	5,650	678
Office and general	7,920	40,708
Interest expense (notes 6 and 7)	50,942	41,752
Stock-based compensation (note 11)	174,459	-
Net loss and comprehensive loss for the period	\$ (394,002)	\$(276,712)
Basic and diluted net loss for the period (note 14)	\$ (0.00)	\$ (0.00)
Weighted average number of common shares outstanding - basic and diluted	80,580,898	63,650,000

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Lophos Holdings Inc.

Condensed Interim Consolidated Statements of Changes in Equity

For the three months ended June 30, 2023 and 2022

(Expressed in Canadian Dollars)

(Unaudited)

	Share Capital		Warrants and special warrants	Contributed surplus	Equity portion of convertible debenture	Deficit	Total
	Number of shares	Amount					
Balance, March 31, 2022	63,650,000	\$ 1,022,322	\$ 1,200,106	\$ 333,090	\$ -	\$ (330,405)	\$ 2,225,113
Net loss for the period	-	-	-	-	-	(276,712)	(276,712)
Balance, June 30, 2022	63,650,000	\$ 1,022,322	\$ 1,200,106	\$ 333,090	\$ -	\$ (607,117)	\$ 1,948,401
Balance, March 31, 2023	79,611,667	\$ 1,981,447	\$ 296,605	\$ 500,701	\$ 15,625	\$ (1,318,120)	\$ 1,476,258
Issuance of shares and warrants in private placements (note 9(b))	1,575,001	139,388	63,112	-	-	-	202,500
Fair value of broker warrants issued in private placement (note 10)	-	(5,276)	5,276	-	-	-	-
Stock-based compensation	-	-	-	174,459	-	-	174,459
Net loss for the period	-	-	-	-	-	(394,002)	(394,002)
Balance, June 30, 2023	79,611,667	\$ 2,115,559	\$ 364,993	\$ 675,160	\$ 15,625	\$ (1,712,122)	\$ 1,459,215

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Lophos Holdings Inc.**Condensed Interim Consolidated Statements of Cash Flows****(Expressed in Canadian Dollars)****(Unaudited)**

Three months ended June 30,	2023	2022
Operating activities		
Net loss for the period	\$ (394,002)	\$ (276,712)
Adjustments for:		
Stock based compensation (note 11)	174,459	-
Forgiveness of loan payable	-	-
Depreciation	7,015	11,176
Accrued interest on promissory notes	38,103	-
Accrued interest on loan payable	5,000	-
Accretion on convertible debenture	7,838	-
Non-cash working capital items:		
Accounts receivable	(4,469)	(54,966)
Accounts payable and accrued liabilities	98,128	89,091
Net cash (used in) operating activities	(67,928)	(231,411)
Investing activities		
Purchase of fixed assets	(54,452)	-
Net cash (used in) investing activities	(54,452)	-
Financing activities		
Proceeds from private placements, net of costs	202,500	-
Repayment of loan payable	-	(40,000)
Proceeds from loan payable	50,000	-
Net cash provided by (used in) financing activities	252,500	(40,000)
Net change in cash	130,120	(271,411)
Cash, beginning of period	140,029	1,001,060
Cash, end of period	\$ 270,149	\$ 729,649

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

1. Business of the Company and going concern

Lophos Pharmaceuticals Corp. ("Lophos Pharma") was incorporated under the *Business Corporations Act* (British Columbia) on September 13, 2021. The registered and head office of Lophos Pharma is located at 550 Burrard St #2900, Vancouver, BC V6C 0A3.

The Company's principal business pertains to the cultivation and research of *Lophophora williamsii* ("peyote cactus"). Additionally, in the long-term, the Company is engaged in the research and development of compounds derived from peyote cactus.

Lophos Holdings Inc. ("Lophos Holdings" or "the Company") was incorporated under the *Business Corporations Act* (British Columbia) on October 14, 2020 under the name "Greenridez 2.0 Acquisitions Corp." and subsequently filed a notice of alteration of its articles in order to change its name to "Lophos Holdings Inc." on February 4, 2022. The registered and head office of the Company is located at 550 Burrard St #2900, Vancouver, BC V6C 0A3.

On December 23, 2021, the Company entered into a Share Exchange Agreement with the shareholders of Lophos Pharma, pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Lophos Pharma in consideration for the issuance of a total of 44,500,000 Common Shares to shareholders of Lophos Pharma in proportion with their respective interest in Lophos Pharma. The acquisition was accounted for as a reverse takeover ("RTO") whereby Lophos Pharma was identified as the acquirer for accounting purpose and accordingly the resulting consolidated financial statements are presented as a continuance of Lophos Pharma. After the RTO, the combined entity of Lophos Holdings and Lophos Pharma is referred to also as "the Company" in these consolidated financial statements.

On December 23, 2021, immediately following the closing of the share Exchange Agreement with the shareholders of Lophos Pharma, the Company entered into a Share Purchase Agreement with certain shareholders of Richmond Pharma Inc. ("Richmond Pharma"), pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Richmond Pharma held by Eric Hancox, Vassil Staykov and Sandra Williams.

On December 23, 2021, immediately following the closing of the share Exchange Agreement with the shareholders of Lophos Pharma, the Company entered into a Share Purchase Agreements with certain shareholders of Richmond Pharma, pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Richmond Pharma held by Herman Holdings Limited ("HHL") in consideration for the issuance of a total of 17,500,000 Common Shares to Herman Holdings Limited. Subsequent to the closing of the acquisition, the Company entered into a debt settlement agreement with Herman Holdings Limited pursuant to which the Company issued 400,000 Common Shares at a deemed value of \$0.10 per Common Share in order to settle an amount of \$40,000 owing to Herman Holdings Limited.

These unaudited condensed interim consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they come due. For the three months ended June 30, 2023, the Company reported a net loss of \$394,002. At June 30, 2023, the Company has cash balance of \$270,149, however the Company's ability to continue as a going concern is dependent upon its ability to develop and maintain profitable operations or to obtain additional financing. There is no assurance that the outcome of these matters will be successful and, as a result, there are material uncertainties that might cause significant doubt regarding the going concern assumption.

These unaudited condensed interim consolidated financial statements do not give effect to any adjustments which would be necessary should the Company be unable to continue as a going concern and therefore be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in the accompanying unaudited condensed interim consolidated financial statements. Such adjustments could be material.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

1. Business of the Company and going concern (continued)

The Company's ability to continue as a going concern is dependent upon raising additional capital to meet its present and future commitments. If additional financing is arranged through the issuance of shares, control of the Company may change and shareholders may suffer significant dilution. In addition, the Company has not generated any revenue to date. These circumstances indicate that material uncertainties exist that may cast significant doubt about the Company's ability to continue as a going concern and, accordingly, the ultimate use of accounting principles applicable to a going concern.

2. Basis of Presentation

Statement of compliance

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full audited annual financial statements.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of August 29, 2023, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as at and for the year ended March 31, 2023, except as noted below. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the year ending March 31, 2024 could result in restatement of these unaudited condensed interim consolidated financial statements.

New accounting policy adopted

Classification of Liabilities as Current or Non-Current (Amendments to IAS 1)

The IASB has published Classification of Liabilities as Current or Non-Current (Amendments to IAS 1) which clarifies the guidance on whether a liability should be classified as either current or non-current. The amendments:

- a. clarify that the classification of liabilities as current or non-current should only be based on rights that are in place "at the end of the reporting period"
- b. clarify that classification is unaffected by expectations about whether an entity will exercise its right to defer settlement of a liability
- c. make clear that settlement includes transfers to the counterparty of cash, equity instruments, other assets or services that result in extinguishment of the liability.

The Company adopted this amendment on April 1, 2023. The adoption of this amendment did not have any significant impact on the unaudited condensed interim consolidated financial statements.

Recent accounting pronouncements

Certain new accounting standards and interpretations have been published that are not mandatory for the current period and have not been early adopted. These standards are not expected to have a material impact on the Company in the current and future reporting periods.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

3. Accounts receivable

Accounts receivable represents Harmonized Sales Tax (HST) receivable.

4. Prepaid expense and advance

As at	June 30, 2023	March 31, 2023
Advance for equipment purchase	\$ -	\$ 210,836
Prepaid expenses	8,372	8,372
Total	\$ 8,372	\$ 219,208

5. Fixed assets

Cost	Building	Computer	Machinery & equipment	Scientific equipment	Furniture & fixture	Land	Total
Balance, March 31, 2022	\$2,521,250	\$ 5,631	\$ 127,528	\$ 431,620	\$ 3,009	\$ 378,750	\$3,467,788
Additions	27,737	-	-	-	-	-	27,737
Balance, March 31, 2023	2,548,987	5,631	127,528	431,620	3,009	378,750	3,495,525
Additions	-	-	-	265,288	-	-	265,288
Balance, June 30, 2023	\$2,548,987	\$ 5,631	\$ 127,528	\$ 696,908	\$ 3,009	\$ 378,750	\$3,760,813
Accumulated depreciation	Building	Computer	Machinery & equipment	Scientific equipment	Furniture & fixture	Land	Total
Balance, March 31, 2022	\$ -	\$ 1,402	\$ -	\$ 5,395	\$ 75	\$ -	\$ 6,872
Depreciation	-	1,269	38,258	-	587	-	40,114
Balance, March 31, 2023	-	2,671	38,258	5,395	662	-	46,986
Depreciation	-	221	6,677	-	117	-	7,015
Balance, June 30, 2023	\$ -	\$ 2,892	\$ 44,935	\$ 5,395	\$ 779	\$ -	\$ 54,001
Net book value	Building	Computer	Machinery & equipment	Scientific equipment	Furniture & fixture	Land	Total
Balance, March 31, 2023	\$2,548,987	\$ 2,960	\$ 89,270	\$ 426,225	\$ 2,347	\$ 378,750	\$3,448,539
Balance, June 30, 2023	\$2,548,987	\$ 2,739	\$ 82,593	\$ 691,513	\$ 2,230	\$ 378,750	\$3,706,812

During the three months ended June 30, 2023, there was no depreciation for building or scientific equipment as they are not in use.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

6. Convertible debenture

On August 31, 2022, the Company issued a convertible debenture with principal of \$150,000 bearing interest at 8% with a maturity date of December 23, 2024. The Company incurred cash issuance costs of \$12,000. The Company allocated \$116,751 of the principal amount, net of cost, to the liability component of the debenture and the remaining amount of \$17,705 to the equity component of the debenture. The Company also issued 80,000 broker warrants in connection with the issuance of the convertible debenture. The fair value of the broker warrants was estimated at \$5,624 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.64%; and an expected life of 2 years.

The continuity of the convertible debenture is as follows:

As at	June 30, 2023	March 31, 2023
Balance, beginning	\$ 126,795	\$ -
Issued	-	132,295
Issuance cost	-	(15,544)
Accretion	4,838	10,044
Balance, ending	\$ 131,633	\$ 126,795

7. Promissory notes

The continuity of the promissory notes are as follows:

As at	June 30, 2023	March 31, 2023
Balance, beginning	\$ 1,909,981	\$ 1,951,434
Interest expense accrued	38,103	152,832
Repayment	-	(194,285)
Balance, ending	\$ 1,948,084	\$ 1,909,981

The promissory notes are unsecured, bear an annual interest rate of 8% and matures on December 23, 2024.

8. Loan payable

During the three months ended June 30, 2023, the Company borrowed a loan payable from Andrew Easdale for a principal amount of \$50,000 with a set interest payment of \$5,000. The loan is due on demand.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

9. Share capital

a) Authorized share capital

Authorized unlimited common shares and unlimited number of preferred shares

b) Common shares issued

	Number of Common Shares	Amount (\$)
Balance, March 31, 2022 and June 30, 2022	63,650,000	1,022,322
Shares issued from conversion of special warrants (i)	15,961,667	1,142,074
Warrants issued upon conversion of special warrants (i)	-	(182,949)
Balance, March 31, 2023	79,611,667	1,981,447
Shares issued in private placement, net of issuance costs (ii)	1,575,001	139,388
Fair value of broker warrants issued in private placement (ii)	-	(5,276)
Balance, June 30, 2023	79,611,667	2,115,559

(i) On January 31, 2023, the Board of Directors resolved to convert, effective as of January 31, 2023, and for no additional consideration and pursuant to the terms of the Special Warrants, all of 15,961,667 Special Warrants issued and outstanding into 15,961,667 Common Shares, 5,333,334 warrants exercisable at \$0.20 per warrant into 5,333,334 common shares of the Company until March 21, 2024 and 333,333 warrants exercisable at \$0.20 per warrant into 333,333 common shares of the Company until November 30, 2024. The holders of the Common Shares issued upon the conversion of the Special Warrants are entitled to the same rights as holders of Common Shares, namely to vote at all meetings of the holders of Common Shares and, subject to the rights of holders of any shares ranking in priority to or on a parity with the Common Shares, to participate rateably in any distribution of the Company's property or assets upon liquidation or winding-up.

The fair value of the 5,333,334 warrants expiring on March 21, 2024 was estimated to be \$167,574 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.91%; and an expected life of 1.14 years. The fair value of the 333,333 warrants expiring on November 30, 2024 was estimated to be \$15,375 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.91%; and an expected life of 1.83 years.

(ii) On May 5, 2023, the Company completed the first tranche of the private placement at which time the company issued an aggregate of 1,500,001 units at \$0.15 for gross proceeds of \$225,000. Each Unit consists of one (1) common share and one (1) common share purchase warrant. Each Warrant entitles the holder to acquire one Common Share at a price of \$0.20 per Common Share for a period of 24 months following the issuance of such Warrant. In connection with the closing, the company paid cash finder fees of \$22,500 and issued 75,000 non-transferable finder warrants entitling the holder to purchase one common share at a price of \$0.20 for a period of two years from closing and 75,000 compensation common shares issued at a deemed value price of \$0.15 per common share.

The fair value of the 1,500,001 warrants expiring on May 5, 2025 was estimated to be \$63,112 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.70%; and an expected life of 2 years. The fair value of the 75,000 warrants expiring on May 5, 2025 was estimated to be \$5,276 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.70%; and an expected life of 2 years.

Lophos Holdings Inc.**Notes to Condensed Interim Consolidated Financial Statements****For the three months ended June 30, 2023****(Expressed in Canadian Dollars)****(Unaudited)**

10. Warrants and broker warrants

The Company issued warrants and broker warrants to acquire common shares as follows:

	Number of Warrants	Weighted Average Exercise Price (\$)
Balance, March 31, 2022 and June 30, 2022	6,213,583	0.10
Issued in connection with the convertible debenture	80,000	0.15
Issued upon conversion of special warrants	5,666,667	0.20
Balance, March 31, 2023	11,960,250	0.15
Issued in private placement (note 9(b))	1,575,001	0.20
Balance, June 30, 2023	13,535,251	0.16

The following table reflects the warrants and broker warrants issued and outstanding as of June 30, 2023:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Warrants Outstanding
November 1, 2023	0.10	0.34	5,000,000
November 15, 2023	0.10	0.38	480,250
March 21, 2024	0.15	0.73	533,333
March 21, 2024	0.20	0.73	5,333,334
August 31, 2024	0.20	1.17	80,000
November 30, 2024	0.20	1.42	333,333
April 6, 2025	0.10	1.77	200,000
May 5, 2025	0.20	1.85	1,500,001
May 5, 2025	0.20	1.85	75,000
	0.16	0.74	13,535,251

On August 31, 2022, the Company issued 80,000 broker warrants in connection with the convertible debenture with each broker warrant exercisable for one common share of the Company at \$0.20 for a period of two years from the date of issuance (note 6).

On January 31, 2023, the Company issued 5,333,334 warrants expiring on March 21, 2024 and 333,333 warrants expiring on November 30, 2024 upon conversion of special warrants.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

11. Stock options

The Company issued stock options to acquire common shares as follows:

	Number of Stock Options	Weighted Average Exercise Price (\$)
Balance, March 31, 2022 and June 30, 2022	-	-
Granted	4,325,000	0.15
Balance, March 31, 2023 and June 30, 2023	4,325,000	0.15

The following table reflects the actual stock options issued and outstanding as of June 30, 2023:

Expiry Date	Exercise Price (\$)	Weighted Average Remaining Contractual Life (years)	Number of Options Outstanding	Number of Options Vested (Exercisable)
January 31, 2028	0.15	4.59	4,325,000	1,081,250

On January 31, 2023, the Board also approved an Option Plan, designed for selected employees, officers, directors, consultants and contractors, to incentivize such individuals to contribute toward the Company's long-term goals, and to encourage such individuals to acquire Common Shares as long-term investments. The Option Plan is administered by the Board. Upon approval of the Option Plan on January 31, 2023, the Company granted 4,325,000 stock options with each option convertible into a Common Share of the Company at a price of \$0.15 per Common Share until January 31, 2028. The terms of any award are determined by the Board, provided that no options may be granted with an exercise price lower than the greater of the closing market prices of the Common Shares on (a) the trading day prior to the date of grant of the stock options, and (b) the date of grant of the stock options. The options vest as to one quarter (1/4) in every three months from the date of grant. The fair value of the stock options was estimated to be \$490,574 using the Black-Scholes valuation model on the following assumptions: dividend yield 0%; volatility 100%; risk-free interest rate 3.04%; and an expected life of 5 years. During the three months ended June 30, 2023, the Company recorded stock-based compensation of \$174,459 (three months ended June 30, 2022 - \$nil).

12. Capital management

The Company considers its capital to be its shareholders' equity. As at June 30, 2023, the Company had shareholders' equity of \$1,459,215. The Company's objective when managing its capital is to seek continuous improvement in the return to its shareholders while maintaining a moderate to high tolerance for risk. The objective is achieved by prudently managing the capital generated through internal growth and profitability, through the use of lower cost capital, including raising share capital or debt when required to fund opportunities as they arise. The Company may also return capital to shareholders through the repurchase of shares, pay dividends or reduce debt where it determines any of these to be an effective method of achieving the above objective. The Company does not use ratios in the management of its capital. There have been no changes to management's approach to managing its capital during the three months ended June 30, 2023.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

13. Fair value and financial risk factors

Risk Management

In the normal course of business, the Company is exposed to a number of risks that can affect its operating performance. These risks, and the actions taken to manage them, are as follows:

Fair Values

The Company has designated its cash as FVTPL which are measured at fair value. Fair value of cash is determined based on transaction value and is categorized as a Level One measurement.

- Level One - includes quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level Two - includes inputs that are observable other than quoted prices included in Level One.
- Level Three - includes inputs that are not based on observable market data.

As at June 30, 2023, the carrying and fair value amounts of the Company's cash are approximately equivalent due to its short term nature. Cash is classified as Level One in the fair value hierarchy as at June 30, 2023.

Credit Risk

Credit risk is the risk of loss associated with a counterparty's inability to fulfill its payment obligations. As at June 30, 2023, management believes that the credit risk with respect to cash and HST receivable is minimal.

Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in satisfying its financial obligations. The Company manages its liquidity risk by forecasting its operations and anticipating its operating and investing activities.

Interest rate Risk

Interest rate risk is the risk that the fair values and future cash flows of the Company will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk to the extent that the cash, if any, maintained at financial institutions is subject to a floating rate of interest. The interest rate risk on cash is not considered significant. The promissory notes and convertible debenture of the Company are not subject to interest rate risk as they bear a fixed interest rate. As at June 30, 2023, a 5% increase (decrease) on the interest rate will result in a corresponding increase (decrease) of approximately \$14,000 in the Company's unaudited condensed interim consolidated statements of loss and comprehensive loss for the three months ended June 30, 2023.

14. Net loss per share

The calculation of basic loss per share for the three months ended June 30, 2023 was based on the loss attributable to common shareholders of \$394,002 (three months ended June 30, 2022 - \$276,712) and the weighted average number of common shares outstanding of 80,580,898 (three months ended June 30, 2022 - 63,650,000).

Diluted loss per share for the three months ended June 30, 2023 does not include the effect of 13,535,251 warrants and broker warrants and 4,325,000 stock options and the promissory note as their effect on the net loss per share would be anti-dilutive.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

15. Related party transactions

(a) Related party balances and transactions

Related parties include the directors of the Company, close family members and enterprises which are controlled by these individuals as well as persons performing similar functions.

Three months ended June 30,	2023	2022
Marrelli Group (i)	\$ 13,612	\$ 8,334
Canalytica Corp. ("Canalytica") (ii)	\$ -	\$ 48,036

(i) During the three months ended June 30, 2023, the Company paid professional fees totaling \$13,612 to Marrelli Support Services Inc. ("Marrelli Support"), and certain of its affiliates, all of which are controlled by Carmelo Marrelli (together known as the "Marrelli Group") for: (i) Remantra Sheopaul to act as the Chief Financial Officer of the Company; (ii) bookkeeping and office support; (iii) corporate secretarial; (iv) transfer agent; and (v) regulatory filing services. Anup Sheopaul is an employee of Marrelli Support. The Marrelli Group was owed \$21,393 (March 31, 2023 - \$1,104) and these amounts were included in amounts payable and accrued liabilities.

(ii) Fees included in professional fees related to the consulting services provided by Canalytica. The Chief Executive Officer of the Company is a director of Canalytica. As at June 30, 2023, \$nil (March 31, 2023 - \$nil) was owed to Canalytica by the Company.

(iii) The Company owed certain shareholder \$21,440 as at June 30, 2023 (March 31, 2023 - \$21,440). The loans are unsecured, non-interest bearing and due on demand.

(iv) The Company issued a convertible debenture (note 6) of \$150,000 to Wolf Acquisition 1.0 Corp. ("Wolf Acquisition"), a company that shares a director with Lophos. As at June 30, 2023, the Company had \$11,115 (March 31, 2023 - \$8,115) accrued interest on the convertible debenture owed to Wolf Acquisition which was included in the accounts payable and accrued liabilities.

(v) The Company issued a convertible debenture (note 6) of \$150,000 to Wolf Acquisition, a company that shares a director with Lophos.

Lophos Holdings Inc.

Notes to Condensed Interim Consolidated Financial Statements

For the three months ended June 30, 2023

(Expressed in Canadian Dollars)

(Unaudited)

15. Related party transactions (continued)

(b) Remuneration of directors and key management

In accordance with IAS 24, key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly, including any directors (executive and non-executive) of the Company. Remuneration of management of the Company was as follows:

Three months ended June 30,	2023	2022
Salaries and benefits	\$ 3,358	\$ 36,204

(c) Major shareholders

To the knowledge of the directors and senior officers of the Company, as at June 30, 2023, no person or corporation beneficially owns or exercises control over common shares of the Company carrying more than 10% of the voting rights attached to all common shares of the Company other than HHL which controls 22% of the Company and Catalytica which controls 14%. The holdings can change at any time at the discretion of the owners.

None of the Company's major shareholders have different voting rights compared to holders of the Company's common shares.

The Company is not aware of any arrangements the operation of which may at a subsequent date result in a change in control of the Company. To the knowledge of the Company, it is not directly or indirectly owned or controlled by another corporation, by any government or by any natural or legal person severally or jointly.

16. Subsequent events

On August 10, 2023, the Company completed the closing of a second tranche of the Concurrent Private pursuant to which it issued 4,170,005 Units, at a price per Unit of \$0.15, for gross proceeds to the Company of \$625,501. Each Unit issued under the closing of the second and final tranche of the Concurrent Private Placement is comprised of one Common Share and one Common Share purchase warrant entitling the holder thereof to acquire one additional Common Share, at an exercise price of \$0.20, for a period of 24 months. The Company also issued 167,666 Broker Warrants to a registered dealer. Each Broker Warrant entitles the holder thereof to acquire one Common Share, at an exercise price of \$0.20, for a period of 24 months. The Company also issued 503,000 Common Shares as compensation, at a deemed issue price of \$0.15, to the same registered dealer.

In addition, on August 11, 2023, the Company received the conditional approval from the Canadian Securities Exchange (CSE) to list the Company's common shares on the CSE. The Company is working to satisfy the remaining conditions for the final listing on the CSE as soon as possible. In this regard, on August 14, 2023, the Company received a receipt from the British Columbia Securities Commission for its final prospectus dated August 11, 2023, thus becoming a reporting issuer in the Province of British Columbia. Finally, Lophos Pharmaceuticals Corp., the Company's wholly owned subsidiary, received its Controlled Substances Dealers License (CSDL) from Health Canada, effective as of August 23, 2023. The Controlled Substances Dealers License (CSDL) permits Lophos Pharmaceuticals to possess, produce, sell/provide, send, transport and deliver the controlled substances covered by the license, namely mescaline, psilocin and psilocybin.